Immune-Related Adverse Events (irAEs): Diagnosis, Management, and Clinical Pearls.

Publication date: Mar 21, 2020

While immune checkpoint inhibitor (ICI) therapy has improved melanoma patient outcomes, it has also resulted in the rise of unique immune-related adverse events (irAEs). Here, we review and synthesize irAE management recommendations from several oncological societies into a streamlined format to aid in diagnosis and management. We also include clinical pearls highlighting several recent research studies in this field.

Knowledge of immunotherapy toxicity has continually evolved, and several major oncologic societies have recently released new or updated guidelines. Keeping up with the evolving field of immunotherapy and related toxicities is crucial, because ICI use, in combination with other agents, will only continue to increase and likely result in new and different patterns of irAEs. Providing clear and concise references for clinicians will help ensure proper irAE evaluation and management going forward. We present one such reference here, covering management of common and/or serious irAEs.

Darnell, E.P., Mooradian, M.J., Baruch, E.N., Yilmaz, M., and Reynolds, K.L. Immune-Related Adverse Events (irAEs): Diagnosis, Management, and Clinical Pearls. 26202. 2020 Curr Oncol Rep (22):4.

Concepts Keywords
ICI Melanoma
Immune Checkpoint Inhibitor Immunosuppression
Immunotherapy Immunotherapy
Melanoma Medicine
Oncological Clinical medicine
Toxicity Cancer treatments
Immune system
Bristol-Myers Squibb
Antineoplastic drugs
Breakthrough therapy
Checkpoint inhibitor


Type Source Name
disease MESH Diagnosis
disease MESH melanoma
pathway KEGG Melanoma
disease MESH Colitis
disease MESH Hepatitis
disease MESH Hypophysitis
disease MESH Hypothyroidism
drug DRUGBANK Ipilimumab
disease MESH Myocarditis
drug DRUGBANK Nivolumab
drug DRUGBANK Pembrolizumab
disease MESH Pneumonitis


Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *